George A J, Spooner R A, Epenetos A A
Dept of Immunology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Immunol Today. 1994 Dec;15(12):559-61. doi: 10.1016/0167-5699(94)90216-X.
Application of monoclonal antibodies (mAbs) to clinical settings has proved to be slower than originally hoped. However, a recent conference provided evidence that the field is coming of age, and that antibodies, and their recombinant derivatives, will continue to find a role in the clinic.
